Skip to content

The Actual News

Stay informed without the news wearing you out.

Experimental pill promises new hope for deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer

Summary

A new pill named daraxonrasib has helped people with advanced pancreatic cancer live longer. In a study, patients taking the pill lived nearly twice as long as those on chemotherapy, with fewer serious side effects.

Key Facts

  • Daraxonrasib blocks a mutated protein that drives tumor growth in over 90% of pancreatic cancer cases.
  • The drug nearly doubled median survival time: 13.2 months versus 6.7 months for chemotherapy.
  • The study involved 500 patients with metastatic pancreatic cancer resistant to prior treatments.
  • Patients taking the pill reported less pain and better quality of life as tumors shrank.
  • Side effects included rash and mouth sores, which affected some patients’ ability to continue treatment.
  • The drug’s maker is Revolution Medicines, and the FDA is speeding up its approval process.
  • The FDA allows expanded access to the drug now for eligible patients.
  • Pancreatic cancer is very deadly, with about 67,000 new U.S. cases and over 52,000 deaths expected this year.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.